Abbott blood glucose test recall receives Class I notice from FDA
This article was originally published in Clinica
The US FDA has given Abbott’s recall of 359 million blood glucose test strips a Class I designation – the most severe category that a medical device recall can receive. Abbott discovered that the test strips may give false low blood glucose results and could potentially cause patients or health care providers to raise their blood glucose unnecessarily. This action could result in serious health consequences, including death. The recall, which was issued in December, covers the firm’s Precision Xceed Pro, Precision Xtra, Medisense Optium, Optium, OptiumEZ, ReliOn and Ultima test strips. The affected tests were manufactured between January and September 2010. Abbott has requested customers to discontinue use of the test strips and return the products.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals